Market revenue in 2023 | USD 48.0 million |
Market revenue in 2030 | USD 214.8 million |
Growth rate | 23.9% (CAGR from 2023 to 2030) |
Largest segment | Autologous therapies |
Fastest growing segment | Autologous Therapies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Autologous Therapies |
Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the China cell therapy market based on autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
China cell therapy market is anticipated to witness significant growth over the forecast period due to increasing demand for ATMPs and the rising attention of industry participants on ATMPs. The companies and authorities operating in the country focus on cell & gene therapy.
For instance, in August 2023, China's National Medical Products Administration (NMPA) approved an Investigational New Drug (IND) application for OriCAR-017 from Oricell Therapeutics. This authorized it to study autologous CAR T-cell therapy for patients suffering from advanced multiple myeloma.
Furthermore, players operating in the country are increasing clinical trials for cell therapies targeting various conditions. For instance, in March 2023, JW Therapeutics initiated a phase 2 clinical trial of relmacabtagene autoleucel injection. Thus, such increasing clinical trials and approvals for cell therapies are anticipated to fuel the competition in the cell therapy market in China.
Horizon Databook provides a detailed overview of country-level data and insights on the China cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into China cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account